Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.83) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.83), Zacks reports. Xenetic Biosciences had a negative return on equity of 43.40% and a negative net margin of 182.99%. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.54 million.
Xenetic Biosciences Price Performance
Shares of NASDAQ XBIO traded down $0.14 during midday trading on Thursday, reaching $3.15. The company’s stock had a trading volume of 59,989 shares, compared to its average volume of 7,299. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.97. The firm has a 50 day moving average price of $3.98 and a 200-day moving average price of $3.98. The stock has a market capitalization of $4.85 million, a P/E ratio of -1.08 and a beta of 2.29.
About Xenetic Biosciences
Featured Stories
- Five stocks we like better than Xenetic Biosciences
- NYSE Stocks Give Investors a Variety of Quality Options
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- The Risks of Owning Bonds
- Jeff Brown’s Exegesis AI Stock Picks
- Where to Find Earnings Call Transcripts
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.